Phibro Animal Health reported first quarter 2027 net sales of $386.8 million, surpassing the consensus estimate of $382.4 million, while adjusted diluted EPS of $0.79 was in-line with analyst expectations. Growth was primarily driven by double-digit revenue increases in the Mineral Nutrition and Performance Products segments, which helped offset regulatory-driven declines in Brazilian medicated feed additive sales.
Key Highlights
- Mineral Nutrition revenue grew 17% to $73.6 million, driven by robust demand and improved average selling prices for trace minerals, zinc oxide, and copper.
- Animal Health sales increased 3% to $293.0 million, as higher demand for medicated feed additives in North America and Asia was partially offset by a $5.2 million decline in Brazil.
- Adjusted EBITDA rose 4% to $64.3 million, though margins were pressured by a 15% increase in SG&A expenses related to employee costs and restructuring activities at the Chicago Heights facility.
- Management reaffirmed its full-year fiscal 2027 guidance, maintaining a net sales target of $1.55 billion to $1.60 billion and adjusted EBITDA of $258 million to $268 million.